ZLDAF (Zelira Therapeutics) Retained Earnings: $-55.32 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLDAF Zelira Therapeutics Ltd ZLDAF
9 GF Score
Price $0.30
GF Value $0.06
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Zelira Therapeutics Retained Earnings?

Zelira Therapeutics ZLDAF 9 Retained Earnings is $-55.32 Mil as of Jun. 2025. GuruFocus rates ZLDAF with a GF Score™ of 9/100 and a GF Value™ of $0.06 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Zelira Therapeutics's retained earnings for the quarter that ended in Jun. 2025 was $-55.32 Mil.

Zelira Therapeutics's quarterly retained earnings increased from Jun. 2024 ($-54.01 Mil) to Dec. 2024 ($-53.04 Mil) but then declined from Dec. 2024 ($-53.04 Mil) to Jun. 2025 ($-55.32 Mil).

Zelira Therapeutics's annual retained earnings declined from Jun. 2023 ($-30.05 Mil) to Jun. 2024 ($-54.01 Mil) and declined from Jun. 2024 ($-54.01 Mil) to Jun. 2025 ($-55.32 Mil).


Zelira Therapeutics  (OTCPK:ZLDAF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Zelira Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Retained Earnings Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.83 -27.54 -30.05 -54.01 -55.32

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.05 -52.81 -54.01 -53.04 -55.32
ZLDAF
9GF Score
Zelira Therapeutics Ltd ZLDAF
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelira Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-55.32 Mil mean?
Zelira Therapeutics (ZLDAF) has a Retained Earnings of $-55.32 Mil as of Jun. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Retained Earnings too high?
Zelira Therapeutics' current Retained Earnings is $-55.32 Mil. Overall, Zelira Therapeutics has a GF Score™ of 9/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zelira Therapeutics' Retained Earnings compare to MTNB and SXTP?
Zelira Therapeutics' Retained Earnings of $-55.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Retained Earnings is $-55.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zelira Therapeutics (ZLDAF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.06, compared to a current price of $0.30 — trading 400% above its estimated fair value. The current Retained Earnings is $-55.32 Mil. Zelira Therapeutics' overall GF Score™ is 9/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Zelira Therapeutics (ZLDAF), the current Retained Earnings is $-55.32 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zelira Therapeutics (ZLDAF) Overvalued in 2026?

Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued. The current stock price of $0.30 is trading 400% above its estimated GF Value™ of $0.06. GuruFocus considers Zelira Therapeutics to be Significantly Overvalued.

Key valuation signals for ZLDAF:

  • Retained Earnings: $-55.32 Mil
  • GF Value™: $0.06 vs. price of $0.30 (400% above fair value)
  • GF Score™: 9/100 with 7 warning signs

No single metric tells the full story. See the ZLDAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zelira Therapeutics Business Description

Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
9GF Score

Get the complete analysis for ZLDAF

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price
$0.06
GF Value